Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology - Mainland China subset analysis of the PIONEER study

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Shi, Yuankai ^a   Li, Junling ^a   Zhang, Shucai ^b   Wang, Mengzhao ^c   Yang, Shujun ^d   Li, Ning ^e   Wu, Gang ^f   Liu, Wei ^g   Liao, Guoqing ^h   Cai, Kaican ⁱ   Chen, Liang'an ^j   Zheng, Meizhen ^k   Yu, Ping ^l   Wang, Xiuwen ^m   Liu, Yunpeng ⁿ   Guo, Qisen ^o   Nie, Ligong ^p   Liu, Jiwei ^q   Han, Xiaohong ^a  

^a CANCER HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d HENAN CANCER HOSPITAL   (China)

^e GUANGZHOU CHEST HOSPITAL   (China)

^f HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^g Medical University   (China)

^h 309TH HOSPITAL OF PLA   (China)

ⁱ SOUTHERN MEDICAL UNIVERSITY   (China)

^j CHINESE PLA GENERAL HOSPITAL   (China)

^k LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

^l SICHUAN CANCER HOSPITAL   (China)

^m SHANDONG UNIVERSITY   (China)

ⁿ CHINA MEDICAL UNIVERSITY   (China)

^o SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^p PEKING UNIVERSITY FIRST HOSPITAL   (China)

^q DALIAN MEDICAL UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EGFR PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASIAN; CHINA; CONTROLLED STUDY; EGFR GENE; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG BIOPSY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; PREDICTION; PROSPECTIVE STUDY; SMOKING; TOBACCO USE; ASIAN CONTINENTAL ANCESTRY GROUP; GENETICS; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MUTATION; PROCEDURES; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84955284455     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143515     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90. doi: 10.3322/caac.20107 PMID: 21296855
2. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, et al. Non-small-cell lung cancer. Lancet. 2011;378:1727-1740. doi: 10.1016/s0140-6736 (10) 62101-0 PMID: 21565398
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer togefitinib. N Engl J Med. 2004;350:2129-2139. doi: 10.1056/NEJMoa040938 PMID: 15118073
4. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500. doi: 10.1126/science.1099314 PMID: 15118125
5. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib anderlotinib. Proc Natl Acad Sci USA. 2004;101:13306-13311. doi: 10.1073/pnas.0405220101 PMID: 15329413
6. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine. 2009;361:947-957. doi: 10.1056/NEJMoa0810699 PMID: 19692680
7. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735-742. doi: 10.1016/s1470-2045 (11) 70184-x PMID: 21783417
8. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98:1817-1824. doi: 10.1111/j.1349-7006.2007.00607.x PMID: 17888036
9. Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res. 2012;18:1947-1953. doi: 10.1158/1078-0432.ccr-11-2511 PMID: 22317764
10. Wu SG, Gow CH, Yu CJ, Chang YL, Yang CH, Hsu YC, et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J. 2008;32:924-930. doi: 10.1183/09031936.00167407 PMID: 18508816
11. Sun YH, Fang R, Gao B, Han XK, Zhang JH, Pao W, et al. Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. Acta Pharmacol Sin. 2010;31:647-648. doi: 10.1038/aps.2010.43 PMID: 20418893
12. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958-967. doi: 10.1056/NEJMoa0904554 PMID: 19692684
13. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). JThoracOncol. 2014;9:154-162. doi: 10.1097/jto. 0000000000000033 PMID: 24419411
14. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866-2874. doi: 10.1200/jco.2010.33.4235 PMID: 21670455
15. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factorfor gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res. 2005;11:3750-3757. doi: 10.1158/1078-0432.ccr-04-1981 PMID: 15897572
16. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, et al. EGFR mutations in nonsmall-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23:857-865. doi: 10.1200/jco.2005.08.043 PMID: 15681531
17. Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 2012;18:1167-1176. doi: 10.1158/1078-0432.ccr-11-2109 PMID: 22228640
18. Li H, Pan Y, Li Y, Li C, Wang R, Hu H, et al. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer. 2013;79:8-13. doi: 10.1016/j.lungcan. 2012.09.018 PMID: 23098378
19. Na II, Park JH, Choedu H, Lee JK, Koh JS. Association of epidermal growth factor receptor mutations with metastatic presentations in non-small cell lung cancer. ISRN Oncol. 2011;2011:756265. doi: 10. 5402/2011/756265 PMID: 22091430
20. Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012;30:433-440. doi: 10.1200/jco.2011.38. 3224 PMID: 22215752
21. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res. 2011;17:1160-1168. doi: 10.1158/1078-0432.ccr-10-2158 PMID: 21233402
22. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012;13:e23-31. doi: 10.1016/s1470-2045 (11) 70129-2 PMID: 21764376
23. Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. JThoracOncol. 2013;8:179-184. doi: 10.1097/JTO.0b013e3182779d18 PMID: 23328547
24. Sasaki H, Endo K, Takada M, Kawahara M, Kitahara N, Tanaka H, et al. EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer. 2007;58:324-328. doi: 10.1016/j.lungcan. 2007.06.024 PMID: 17686547
25. Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol CancerTher. 2013;12:220-229. doi: 10.1158/1535-7163.mct-12-0620 PMID: 23371856